<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Koblan, Kenneth S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dasotraline Is Clinically Effective for Adults With ADHD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-11 13:08:33</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3-4</style></pages><abstract><style  face="normal" font="default" size="100%">Adults with attention deficit hyperactivity disorder may benefit from an oral regimen of dasotraline, which inhibits reuptake of dopamine and norepinephrine. Deficiencies of both compounds have been associated with attention deficit hyperactivity disorder symptoms. The 4-week, randomized, double-blind, placebo-controlled trial provided proof-of-concept for dasotraline use, and should prompt further clinical trials and dose optimization.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>